Pricing Log in Create free account
Saturday 17 October 2026 Export MRNA’s income statement to Excel — free account

Moderna, Inc.

MRNA Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.

218.01 18.49 −7.82%
Market cap
$94.4B
P/E
0.0×
Fwd P/E
−5.5×
Dividend yield
—
F-score
3/9
Altman Z
2.46
Beneish M
−3.52
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Moderna, Inc. 10-K filed Feb 20, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:02 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 21, 2025: 82 added · 111 removed · 129 modified; 6 with only figures updated

  1. Modified

    Moderna is a pioneer and leader in the creation of the field of messenger RNA (mRNA) medicine. Through the advancement of mRNAour technology platform, we are reimagining how medicines are made and transformingto transform how we treat and prevent disease for everyonediseases. By working at the intersection of scienceSince our founding, technology and health for more than a decade, we have developed medicines at unprecedented speed and efficiencyour mRNA platform has enabled the development of vaccine and therapeutic candidates across infectious disease, oncology, including one of the earliest rare disease and most effective COVID vaccinesmore.

321 more changes in this Item, word by word, in Powerpack.

Powerpack